Aims: Basal-bolus therapy is associated with greater treatment burden and lower adherence compared with more simplified regimens. This post hoc analysis studied the difference between insulin degludec/liraglutide (IDegLira) and basal-bolus therapy on number of injections, dose adjustments and patient outcomes in the DUAL VII trial. Materials and methods: DUAL VII was a 26-week, open-label trial in which patients with uncontrolled type 2 diabetes who were using metformin and insulin glargine 100 units/mL (20-50 U) were randomized 1:1 to IDegLira (N = 252) or basal-bolus (insulin glargine U100 + insulin aspart ≤4 times/day) (N = 254). This post hoc analysis reports the observed mean number of injections and cumulative dose adjustments during 26 weeks of treatment. Patient-reported outcomes (Treatment-Related Impact Measure -Diabetes [TRIM-D] and Short Form-36 Health Survey version 2 [SF-36v2]) were collected at scheduled visits and change from baseline scores calculated.
However, this is often delayed, a phenomenon referred to as clinical inertia. 1, 2 One of the reasons for clinical inertia is the desire on the part of healthcare professionals (HCPs) and patients to avoid increasing treatment burden. 3 Studies have shown that increased treatment burden is associated with poorer adherence to treatment. [4] [5] [6] An improvement in adherence with fewer injections has been seen in a study in patients with T2D, which found that patients receiving basal insulin were more likely to persist with insulin therapy compared with patients on basal-bolus regimens (discontinuation rates of 28.7% compared with 35.4% after 12 months, excluding deaths, for basal insulin and basal-bolus therapy, respectively). 7 Poor adherence to treatment is a serious concern in clinical practice 5 as it has been associated with smaller reductions in glycated haemoglobin (HbA1c) levels, 8 increased emergency room visits and admissions, and longer hospital stays. 9, 10 Insight into the patient's perspective on various treatment regimens can contribute to individualizing therapy and, potentially, to improving adherence.
The availability of glucagon-like peptide-1 receptor agonists (GLP-1RAs), injectable incretin mimetics that lower fasting and post-prandial blood glucose in a glucose-dependent manner, provides patients who have uncontrolled T2D with basal insulin an effective intensification option that offers a lower treatment burden, a reduced risk of hypoglycaemia, and weight loss or weight maintenance as opposed to weight gain, compared with intensifying therapy with prandial insulin. [11] [12] [13] Fixed ratio combination (FRC) injectable therapies with basal insulin/GLP1-RA therapy provide these advantages and further reduce treatment burden. [14] [15] [16] [17] [18] [19] [20] [21] Results from the DUAL clinical trial programme demonstrated that the FRC IDegLira combines the benefits of the basal insulin degludec (degludec) and the GLP-1RA, liraglutide, in a single daily injection, with a stepwise titration algorithm that contributes to attenuating the primary side effects associated with each component. [14] [15] [16] [18] [19] [20] [21] The DUAL VII trial compared the efficacy and safety of IDegLira with basal-bolus ther-
apy (insulin glargine 100 units/mL [IGlar U100] + insulin aspart [IAsp] ≤4
times daily) in patients with T2D who were inadequately controlled with basal insulin and metformin. 20 IDegLira, administered as a once-daily injection, was non-inferior (P < .0001) to the multiple injections of basalbolus therapy in reducing HbA1c from baseline (67 mmol/mol [8.2%]) to end of study (50 mmol/mol [6.7%]). Furthermore, treatment with IDegLira resulted in weight loss compared to the weight gain with basalbolus therapy (−0.9 kg compared with +2.6 kg; P < .0001), and in fewer hypoglycaemic episodes (1.07 compared with 8.17 severe or blood glucose confirmed symptomatic hypoglycaemic episodes per patient year with IDegLira and basal-bolus, respectively; P < .0001). 20 Also of note, the cardiovascular safety of each component has been confirmed in their respective cardiovascular outcome trials. 22, 23 Degludec demonstrated non-inferiority to IGlar U100 22 and liraglutide in reducing the risk of major adverse cardiovascular events compared with placebo. 23 Furthermore, post hoc sub-analyses of the DEVOTE 24 and DUAL programme 25 were in agreement with these findings, suggesting that cardiovascular safety was preserved.
The DUAL VII trial showed that IDegLira is as efficacious in reducing mean HbA1c as basal-bolus therapy, with fewer injections. In this study, we performed a post hoc analysis of the DUAL VII trial, which aimed to evaluate the extent to which the clinical benefits of IDegLira were achieved with a simpler dosing regimen in terms of number of injections and dose adjustments. Additionally, we looked at results from patient-reported outcome (PRO) questionnaires to assess the effect of each treatment on patients' self-perceived health status.
| MATERIALS AND METHODS

| Study design and interventions
The DUAL VII clinical trial programme (Clinical trial registration: NCT02420262) was an open-label, multinational, two-arm parallel, randomized trial in patients with T2D that was conducted at 89 sites in 12 countries from July 2015 to October 2016. Study design and methodology have been published previously ( Figure 1 ). 20 Eligible patients were at least 18 years old with uncontrolled T2D (HbA1c, 53-86 mmol/mol [7.0%-10.0%]), with a BMI ≤40 kg/m 2 , who were receiving stable daily doses of 20-50 units (U) of IGlar U100 and at least 1500 mg (or maximum tolerated dose) of metformin for more than 90 days prior to screening. 20 Patients were randomized to receive either 16 U of IDegLira (16 U insulin degludec +0.58 mg liraglutide) or to continue using basal IGlar U100 at the pre-trial dose (mean pre-trial insulin dose of 33 U) with the addition of IAsp four or fewer times daily. Metformin was continued at the pre-trial dose in both treatment arms ( Figure 1 ). 20 Both IDegLira and IGlar U100 were titrated twice weekly, using the same titration algorithm based on the mean of three consecutive pre- 
| Patient-reported outcomes
PROs were collected at three scheduled visits (baseline, week 12 and week 26) and domain summary scores and change from baseline in summary scores were calculated. PRO questionnaires included the Treatment-Related Impact Measure for Diabetes (TRIM-D), comprising 28 items in five domains and a total score, 28, 29 and the Short Form-36 Health Survey version 2 (SF-36 v2), consisting of 36 items in eight domains with two component summary scores. 30 TRIM-D scales (domain and total score) range from 0 to 100, with a higher score corresponding to a better outcome. 29 The minimally important difference (MID), defined as the smallest difference detected by patients, for TRIM-D has not been established. SF-36 scores were calculated using a 1998 reference population norm, in which a score of 50 corresponded to the norm for the adult general US population; higher scores corresponded with better outcomes. 30 The MID thresholds for SF-36 were taken from the user manual and ranged from 2 to 4; they were not specific to patients with diabetes. 31 
| Statistical analysis
| RESULTS
The treatment arms were well matched with respect to baseline characteristics. 20 Of the 506 patients who were randomized to treatment, 94.4% (238/252) in the IDegLira arm and 91.7% (233/254) in the basal-bolus arm completed treatment.
| Regimen complexity
With IDegLira being initiated at 16 U and IGlar U100 being titrated from the pre-trial basal dose (mean 33 U) 20 (Figure 2 ), a similar number of adjustments in basal dose were observed for patients treated with IDegLira compared to those treated with IGlar U100 (16.6 compared with 17.1 adjustments, respectively, for the duration of the trial). Mean end-of-trial basal insulin dose was 40.4 U for IDegLira (40.4 U degludec and 1.5 mg liraglutide) and 52.3 U for IGlar U100.
There were more dose adjustments for patients treated with IDegLira early in the trial compared with patients treated with IGlar U100.
However, the number of dose adjustments in patients treated with IDegLira began to reduce at approximately Week 10, whereas reduction did not take place until Week 18 in patients treated with IGlar U100 ( Figure 3A (Figure 4 ). As these patients were also receiving a basal insulin injection, at Week 26 over 90% (209/230, 90.9%) of patients in this treatment arm were receiving three or more injections daily.
| Treatment-related impact measure -Diabetes
Improvements across all TRIM-D domains as well as in the total score were significantly greater (P ≤ .0268) with IDegLira compared with basal-bolus treatment ( Figure 5 ). Patients in the IDegLira treatment group showed moderate improvements across all TRIM-D domains and in the total score, while patients in the basal-bolus treatment group showed small improvements in the total score and across all domains, with the exception of daily life. The greatest differences between groups were in diabetes management (ETD: 10.76, P < .0001), treatment burden (ETD: 10.50, P < .0001) and compliance (ETD: 6.25, P < .0001). These domains include questions such as "How satisfied or dissatisfied have you been with the ease and convenience of your medication?" (treatment burden domain) and "How satisfied or dissatisfied 
| Short Form-36 Health Survey version 2
Results of the SF-36 v2 showed improvements in both treatment arms 31 No statistically significant differences between treatment arms were seen in the physical component summary or in any of the physical domains (Table S1 ). In addition, none of the differences in the physical component summary reached MID thresholds. While it is unlikely that insulin dose would be adjusted as frequently in clinical practice as is described here, it is evident that basal-bolus therapy necessitates more adjustments and, therefore, more dosing decisions than treatment with IDegLira. This is consistent with the primary DUAL VII results, which demonstrated that patients treated with IDegLira reached a stable insulin dose earlier and required a lower total daily insulin dose compared with patients in the basal-bolus treatment group, with similar reductions in HbA1c and improved clinical outcomes overall 20 without the added complexity. It is also worth noting that, in the DUAL VI trial, 19 a simpler once-weekly titration algorithm for IDegLira was compared with the twice-weekly algorithm used in all other DUAL trials in insulin-naïve patients; it was found that onceweekly titration of IDegLira, based on the average of two fasting blood glucose readings, resulted in a safety profile and a glycaemic efficacy profile similar to those with twice-weekly titration, based on the average of three fasting blood glucose readings. 19 This evidence suggests that IDegLira also has the potential to be as efficacious as basal-bolus IDegLira treatment, as adherence to a treatment regimen is typically greater with simpler regimens. 33 There was also a trend for improvements in the generic SF- This study also has several limitations. The DUAL VII trial was open-label, which may have had an influence on study outcomes.
| DISCUSSION
However, blinding would have required additional placebo injections in the IDegLira arm and this would put unnecessary burden on patients and prevent an analysis of PROs. A second limitation is that the improvements in PRO scores, which were observed across all domains with IDegLira treatment and across the majority of domains with basal-bolus therapy, may be a clinical study effect, with participants in both treatment arms achieving good glycaemic control and receiving clinical support, which does not necessarily reflect realworld conditions. A third limitation is that the compliance domain scores should be interpreted with caution because of the subjective nature of the questions. For example, "How often do you delay or postpone taking your medication? never/almost never, rarely, sometimes, often or almost always/always?". A further limitation of this study is that the analysis of PROs was not adjusted for multiplicity and, as a result, there is a potential for inflated type 1 error.
In conclusion, this post-hoc analysis demonstrates that treatment with IDegLira is a simple regimen, requiring fewer daily injections, fewer SMBG readings and fewer dose adjustments, and this is likely to be responsible, in part, for the observed improvement in the PROs of patients treated with IDegLira as compared with those receiving basalbolus therapy. Taken together, these results and the improved clinical outcomes (non-inferior HbA1c, fewer episodes of hypoglycaemia and weight benefit) demonstrated with IDegLira treatment 20 suggest that it is less burdensome than basal-bolus therapy and has potential to improve patient adherence and compliance. In clinical practice, a treatment that requires fewer adjustments and measurements may facilitate timely achievement of glycaemic control.
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